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Abstract
Introduction: Paclitaxel (Taxol®) is a microtubule-targeted agent that is widely used for cancer treatment. However,
resistance to paclitaxel is frequently encountered in the clinic. There is increasing interest in identifying compounds
that may increase the sensitivity to conventional chemotherapeutic agents. In this study, we investigated whether
green tea polyphenol (-)-epigallocatechin gallate (EGCG) could sensitize breast carcinoma to paclitaxel in vivo.
Methods: Breast cancer cells were treated with or without EGCG and paclitaxel followed by detection of cell
survival and apoptosis. c-Jun NH2-terminal kinase (JNK) phosphorylation and glucose-regulated protein 78 (GRP78)
expression were detected by Western blotting. For in vivo study, 4T1 breast cancer cells were inoculated into Balb/
c mice to establish a transplantation model. The tumor-bearing mice were treated with or without EGCG (30 mg/
kg, i.p.) and paclitaxel (10 mg/kg, i.p.). Tumor growth was monitored. Apoptosis in tumor tissues was detected. Cell
lysates from tumors were subjected to Western blot analysis of GRP78 expression and JNK phosphorylation.
Results: EGCG synergistically sensitized breast cancer cells to paclitaxel in vitro and in vivo. EGCG in combination
with paclitaxel significantly induced 4T1 cells apoptosis compared with each single treatment. When tumor-bearing
mice were treated with paclitaxel in combination with EGCG, tumor growth was significantly inhibited, whereas
the single-agent activity for paclitaxel or EGCG was poor. EGCG overcame paclitaxel-induced GRP78 expression and
potentiated paclitaxel-induced JNK phosphorylation in 4T1 cells both in vitro and in vivo.
Conclusions: EGCG may be used as a sensitizer to enhance the cytotoxicity of paclitaxel.
Introduction
Paclitaxel (taxol) is a plant alkaloid commonly used in
the treatment of human tumors [1]. It binds with high
affinity to the b-subunit of tubulin and results in
decreased dynamic instability and increased microtubule
rigidity [2]. Taxol has demonstrated activity in a variety
of solid tumors, particularly ovarian and breast cancer
[3]. The mechanism of action of taxol is a premature
stabilization of microtubule assembly, which disrupts
the cytoskeletal framework necessary for tumor-cell
replication and metastatic spread [4]. As a promoter of
tubulin polymerization, taxol changes the dynamic
equilibrium between assembly and disassembly of
microtubules, disrupts the formation of the normal spin-
dle at metaphase, and causes the blockade of mitosis at
the G2/M phase [5]. Clinical practice has demonstrated
that taxol plays an important role in both first-line and
second-line treatment of patients with ovarian cancer
and metastatic cancer of the breast [6,7]. Taxol has
well-established single-agent activity in the first-line
treatment of women with advanced breast cancer, with
response rates for standard dose therapy ranging from
25% to 29% [8,9].
Resistance to taxol is frequently encountered in the
clinic. The identification of chemosensitizers for cancer
chemotherapy is an area of intensive investigation. Her-
bal remedies, including green tea, are emerging as popu-
lar agents for cancer patients dealing with side effects of
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gic, clinical and laboratory studies have revealed an
inverse-relationship between increased green tea intake
and the relative risk for cancer [10-12]. The chemopre-
ventive effects of green tea have been attributed to poly-
phenolic ingredients that have potent antioxidant
properties. Among many polyphenolic compounds iso-
lated from green tea, (-)-epigallocatechin gallate (EGCG)
is recognized as a key active constituent in terms of can-
cer chemopreventive potential. It is reported that 1.0 ×
10
-4 M EGCG can significantly inhibit the growth of
acute myeloblastic leukemia cells and induce apoptosis
in human cancer cells [13,14]. Although cancer cell
lines exhibit variable sensitivity to EGCG [15], EGCG is
more and more seen as a possible new tumor-suppres-
sing and anti-carcinogenic natural chemical. Many stu-
dies showed that EGCG inhibited the survival rate of
malignant cells and induced apoptosis of malignant cells
via the mitochondrial signal transduction pathway
[16,17]. Roy et al. [18] reported that the increased ratio
of Bax/Bcl-2 proteins after EGCG treatment might
result in increased release of cytochrome C from mito-
chondria into cytosol, increase the expression of Apaf-1,
and activate caspase-3 and poly (ADP-ribose) polymer-
ase, which could lead to apoptosis in MDA-MB-468
cells.
An in vitro study demonstrated that EGCG could sen-
sitize glioma cells to temozolomide [19]. However,
EGCG reportedly blocks chemotherapy benefit of borte-
zomib and other boronic acid-based proteasome inhibi-
tors. These detrimental effects of EGCG may be
mediated by a direct interaction between EGCG and
bortezomib thereby preventing bortezomib hitting its
targets in tumor cells [20]. Therefore, it appears that
EGCG can be beneficial or detrimental when it is used
in combination with other agents, depending on the nat-
ure of these compounds. Many proteins have been iden-
tified as EGCG targets. One of EGCG target proteins is
glucose-regulated protein 78 (GRP78), an endoplasmic
reticulum (ER) chaperone that belongs to the Hsp70
family [21]. GRP78 is a key regulator of ER homeostasis
due to its critical roles in protein folding, ER calcium
binding, and activating transmembrane ER stress sensors
[22]. As a multifunctional chaperone, GRP78 promotes
tumor cell proliferation, survival, metastasis, and resis-
tance to a variety of therapies [23]. Combination therapy
suppressing GRP78 expression and activity may repre-
sent an approach toward improvement of the effective-
ness of cancer therapy. Recently, we and others
demonstrated that taxol could induce GRP78 overex-
pression, XBP-1 splicing, and eIF2a phosphorylation,
hallmarks of the unfolded protein response [24,25].
GRP78 knockdown potentiates taxol-induced JNK phos-
phorylation and protects breast cancer cells against
paclitaxel-induced apoptosis [24]. In this regard, GRP78
may be a novel target to overcome taxol resistance.
Based on these earlier findings, we initiated this study to
investigate whether EGCG is able to enhance the anti-
tumor effects of taxol in vivo.
Materials and methods
Reagents
Paclitaxel (Taxol) were purchased from Sigma-Aldrich,
Inc. (St. Louis, MO, USA). Ninety-nine percent pure
EGCG was purchased from MUST Biotech. (Chengdu,
China). The phosphorylated JNK antibody and JNK inhi-
bitor SP600125 were provided by Cell Signaling (Beverly,
MA, USA). GRP78 and b-actin antibodies were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA).
Cell culture
Breast cancer cell lines (4T1, MCF-7, and MDA-MB-
231) were originally obtained from the American Tissue
Culture Collection. Tumor cells were grown in tissue
culture flasks at 37°C in a humidified atmosphere of 5%
CO2 and were maintained as monolayer cultures in Dul-
becco’s minimal essential medium supplemented with
5% fetal bovine serum, 100 U/mL penicillin and 100 μg/
mL streptomycin.
4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,
3-benzene disulfonate (WST-1) assay
Cells were plated in 96-well plates at 5,000 cells per
well. The next day, cells were treated with or without
taxol and 20 μM EGCG in four replicates. After 24 or
48 h, cell viability was assessed by incubating cells with
WST-1 reagent (Roche, Indianapolis, IN, USA) for 2 h
and measuring the absorbance at 450 nm, and at 630
nm as reference, with a microplate reader (Bio-Rad,
Hercules, CA, USA).
Hoechst 33342 staining
Replicate cultures of 1 × 10
6 cells per well were plated
in 24-well plate. The cells were treated with or without
20 μM EGCG, 1 μM taxol and 10 μM SP600125. After
a change of fresh medium 24 h later, the cells were
incubated with 5 μL of Hoechst 33342 solution per well
at 37°C for 10 minutes, followed by observation under a
fluorescence microscope. Strong fluorescence can be
observed in the nuclei of apoptotic cells, while weak
fluorescence was observed in non-apoptotic cells. Quan-
tification of apoptotic cells was performed by counting
cells in four random fields in each well.
Western blot
For cell cultures, cells were treated with 1 μM taxol, 20
μM EGCG, or combination for 24 h. The cells were
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vested with cold lysis buffer containing protease inhibi-
tors or phosphatase inhibitors. Cell lysates were
collected from culture plates using a rubber policeman,
and protein collected by centrifugation. For tumor sam-
ples, tumor tissues were homogenized in lysis buffer
containing protease inhibitors, and protein collected by
centrifugation. Protein concentrations were determined
by BCA protein assay (Pierce Biotechnology, Rockford,
IL, USA). Forty micrograms of total protein were boiled
in 2× loading buffer (0.1 M Tris-Cl, pH 6.8, 4% SDS,
0.2% bromophenyl blue, 20% glycerol) for 10 minutes,
then loaded into Tris-HCl-Polyacrylamide gels, and
transferred electrophoretically to Immobilon-P mem-
brane (Millipore Corporation, Billerica, MA, USA).
Membranes were incubated with primary antibodies and
appropriate horseradish peroxidase-labeled secondary
antibodies. Membranes were additionally probed with
an antibody against b-actin (Santa Cruz Biotechnology)
to normalize loading of protein among samples. The
secondary antibodies were detected by chemilumines-
cent agents (Pierce Biotechnology).
Determination of tumor inhibition in a murine model of
mammary carcinoma
A l la n i m a ls t u d i e sw e r ep e rformed according to the
guidelines and approval of the Institutional Review
Board of West China Hospital. Six- to seven-week-old
female Balb/c mice were used for all experiments. The
mice were housed in groups of four to five animals
per cage. To establish tumor grafts, subconfluent
breast cancer cells 4T1 were dispersed with 0.1% tryp-
sin/EDTA and washed once with medium containing
5% calf serum to remove the trypsin. The cells were
resuspended at a concentration of 8 × 10
5 cells/mL in
phosphate-buffered saline. A total of 8 × 10
4 breast
cancer cells were injected subcutaneously and per-
mitted to grow until palpable. At that time, the mice
were randomly assigned into control and treatment
groups and chemotherapy was initiated. The doses
and route of administration for EGCG and taxol were
chosen according to reports by Scandlyn et al [26] and
Wang et al [27], respectively. EGCG (30 mg/kg) was
delivered intraperitoneally everyday, while taxol (10
mg/kg) was given intraperitoneally every two days.
Control animals received an injection of 0.9% saline
solution in volumes equivalent to those used for injec-
tion of the drugs.
Two-dimensional measurements were taken with cali-
pers during the treatment period, and tumor volume
was calculated with the use of the following formula:
tumor volume (mm
3)=a×b
2 ×0 . 5 2 ,w h e r ea is the
longest diameter, b is the shortest diameter. At the end
of the experiments, the mice were sacrificed by carbon
dioxide aspiration, the tumors were dissected, fixed in
formalin, and embedded in paraffin. Visible metastatic
foci in the lungs were counted.
DNA fragmentation detection
Cell apoptosis in tumor tissues was analyzed using the
Fluorescein-FragEL™ DNA Fragmentation Detection Kit
(Calbiochem, San Diego, CA, USA) according to the
manufacturer’s instruction. The apoptotic index was
evaluated by the percentage of cells scored under a light
microscope at 200-fold magnification.
Statistical analysis
A two-way repeated measures ANOVA was used to test
for the differences in tumor growth. One-way ANOVA
was used to test for the difference in the means of apop-
tosis rate, tumor weight, and metastasis. All statistical
tests were two-tailed, and difference to be considered to
be statistically significant when P < 0.05.
Results
EGCG sensitizes breast cancer cells to taxol-induced
apoptosis
First, we determined the sensitivity of three breast can-
cer cell lines (4T1, MCF-7, and MDA-MB-231) to taxol.
Among three cell lines, 4T1 was less sensitive to taxol
than MCF-7 and MDA-MB-231 (Figure 1a). Next, the
effect of EGCG, taxol and a combination of the two on
cell survival was examined by WST1 assay. Treatment
of 4T1 and MDA-MB-231 cells with EGCG in combina-
tion with taxol led to a dramatic decrease in cell viability
compared to treatment with taxol alone (Figure 1b and
1c). To determine whether the combination of EGCG
and taxol can synergistically promote apoptosis in 4T1
cells, the effect of EGCG, taxol and combination on
apoptosis was examined by Hoechst 33342 staining. The
results demonstrated that treatment of 4T1 cells with
EGCG in combination with taxol led to a dramatic
increase in cell apoptosis compared to treatment with
taxol alone (Figure 2a and 2b).
Previous studies have demonstrated that JNK activa-
tion is involved in taxol-induced apoptosis. Here, we
found that JNK inhibitor also suppressed the stimulatory
effects of EGCG on taxol-induced apoptosis in 4T1 cells
(Figure 2a and 2b). To determine whether EGCG indeed
affect taxol-induced JNK phosphorylation in 4T1 cells,
the cells were treated with EGCG, taxol, or both. Treat-
ment with EGCG alone did not induce JNK phosphory-
lation. However, a combination of EGCG and taxol
resulted in higher levels of phosphorylated JNK than
that in cells treated with taxol alone (Figure 2c). Treat-
ment with SP600125 reduced the levels of phosphora-
lated JNK. These results demonstrated that EGCG could
potentiate the activation of JNK by taxol.
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Page 3 of 10Figure 1 EGCG sensitizes breast cancer cells to taxol. (a) Sensitivity of 4T1, MDA-MB-231 and MCF-7 cells to taxol. Cells were treated with
increasing doses of taxol (0.1 to 2 μM) for 24 h. Cell viability was assessed by WST1 assay. Points = mean of four replicates; bars = SE. Asterisk =
P < 0.01 versus untreated controls. (b) 4T1 cells were seeded in a 96-well plate at 5,000 cells per well. The next day, the cells were treated with
20 μM EGCG, 1 μM taxol, or a combination for 48 h. Cell viability was assessed by WST1 assay. Points = mean of four replicates; bars = SE.
Asterisk = P < 0.01 versus untreated control. Triangle = P < 0.001 versus single agent. (c) MDA-MB-231 cells were seeded in a 96-well plate at
5,000 cells per well. The next day, the cells were treated with 20 μM EGCG, 1 μM taxol, or combination for 48 h. Cell viability was assessed by
WST1 assay. Points = mean of four replicates; bars = SE. Asterisk = P < 0.001 versus untreated control. Triangle = P < 0.001 versus single agent.
Figure 2 EGCG potentiates taxol-induced apoptosis in 4T1 cells. (a) 4T1 cells were treated with 20 μM EGCG, 1 μM taxol, 10 μM SP600125
or combination for 24 h, and apoptosis was assessed by Hoechst 33342 staining. The apoptotic cells with strong fluorescence or fragmented
nuclei were observed under fluorescent microscopy. (b) Quantification of apoptotic cells was performed by taking the images in random fields
and counting cells with strong fluoresence or fragmented nuclei. The relative apoptosis rate was plotted. Columns = mean percentage of
apoptotic cells; bars = SE. Asterisk = P < 0.001 versus untreated control or taxol in combination with 10 μM SP600125. Black triangle = P < 0.001
versus EGCG, taxol, or taxol in combination with EGCG and SP600125. (c) 4T1 cells were treated with 20 μM EGCG, 1 μM taxol, EGCG in
combination with taxol, taxol in combination with 10 μM SP600125, or taxol in combination with EGCG and SP600125 for 24 h. Total proteins
were harvested with lysis buffer containing phosphatase inhibitor, and subjected to Western blot analysis of JNK phosphorylation. The ratio of p-
JNK/actin as determined by densitometric analysis was given. (d) 4T1 cells were treated with 20 μM EGCG, 1 μM taxol, or EGCG in combination
with taxol for 24 h. Total proteins were harvested and subjected to Western blot analysis of GRP78 expression. The ratio of GRP78/actin as
determined by densitometric analysis was given. Representative of two experiments was shown.
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docetaxel can induce GRP78 expression [22,23]. GRP78
knockdown potentiated taxol-induced JNK phosphoryla-
tion and cell apoptosis [22]. To determine the effect of
EGCG on taxol-induced GRP78 expression, we checked
the levels of GRP78 in 4T1 cells treated with EGCG,
taxol, or both. The result demonstrated that EGCG sup-
pressed taxol-induced GRP78 expression (Figure 2d).
EGCG sensitizes breast carcinoma to taxol in vivo
To determine whether EGCG can improve the thera-
peutic effects of taxol on breast carcinoma in vivo,t h e
effect of combination treatment with EGCG and taxol
on mammary tumorigenesis was evaluated in a murine
breast cancer (4T1) model in Balb/c mice. When tumors
were palpable, therapy with EGCG was initiated at 30
mg/kg body weight everyday, and therapy with taxol
was initiated at 10 mg/kg body weight every two days.
Combination treatment with EGCG and taxol was also
initiated. Control mice received 0.9% saline solution.
Tumors were not sensitive to taxol at the given dose.
Whereas taxol or EGCG alone had little effect on tumor
growth, the combination of EGCG and taxol signifi-
cantly inhibited tumor growth (Figure 3). These data
demonstrated that EGCG could sensitize 4T1 tumors to
taxol in vivo.
Figure 3 EGCG sensitizes 4T1 tumors to taxol in Balb/c mice. (a) 4T1 cells were injected into Balb/c mice as described in Materials and
Methods. When tumors became palpable, the mice were randomly assigned into different groups (n = 8 for control; n = 8 for EGCG group; n =
8 for taxol group; n = 10 for combination treatment), and treated with EGCG (30 mg/kg), taxol (10 mg/kg), or both. Tumor growth was
monitored for 24 days. Asterisk = P < 0.05, significantly different from control, EGCG, or taxol group (two-way ANOVA, post-hoc test). Data are
mean ± SE. (b) Tumors were dissected 24 days after inoculation of tumor cells into the mice. The tumor weight was measured. The combined
data of tumor weight from two experiments was plotted (n = 15 for control; n = 15 for EGCG group; n = 15 for taxol group; n = 16 for
combination treatment). Columns = mean of tumor weight; bars = SE. Asterisk = P < 0.05, significantly different from control or single agent.
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treatment with EGCG and taxol on lung metastasis.
Twenty-four days after inoculation of 4T1 cells in
Balb/c mice, the tiny metastatic foci in the lung surface
were observed. After counting visible metastasis, we
found that the median of metastasis by treatment was
as follows: control, 5 (95% confidence interval (CI), 0
to 15.7); EGCG, 3; (95% CI, 0 to 5.7); taxol, 7.5 (95%
CI, 0 to 16.9); and EGCG plus taxol, 2 (95% CI = 0 to
3.9). There was no significant difference between the
control group and taxol- or EGCG-treated group,
w h i l et h ed i f f e r e n c eb e t w e e nt h ec o n t r o lg r o u pa n d
combination treatment group was marginally signifi-
cant (P = 0.053).
Animals treated with EGCG and taxol had no signifi-
cant changes in weight (data not shown), suggesting no
overt systemic toxicity. In addition, systematic examina-
tion of major organs revealed no histological changes
indicative of drug toxicity, including liver, spleen, heart,
and kidneys.
EGCG promotes taxol-induced apoptosis and overcomes
taxol-induced GRP78 expression in tumor tissues
We detected the apoptosis indices in tumor tissue by in
situ DNA fragmentation assay. The control tumors had
an average apoptosis index of 1.5%. The EGCG-treated
tumors had an average apoptosis index of 1.8%. The
taxol-treated tumors had an average apoptosis index of
4.2%. The tumors that were treated with both EGCG
and taxol had an average apoptosis index of 12.1% (Fig-
u r e4 ) .I na d d i t i o n ,w ed e t e r mined the proliferation
index of tumor cells by immunostaining tumor sections
for proliferating cell nuclear antigen, a nuclear marker
for proliferative cells. There was no significant difference
in the proliferation indices among these groups of
tumors (data not shown).
Previously, our in vitro study demonstrated that taxol
up-regulated the expression of the endoplasmic reticu-
lum chaperone GRP78, one of EGCG targets. To deter-
mine whether EGCG and taxol affect GRP78 expression
in tumor tissues, we detected GRP78 levels in tumors by
Western blotting. Overall, the levels of GRP78 protein
tend to be increased in taxol-treated tumors (Figure 5).
The levels of GRP78 in tumors treated with both EGCG
and taxol were lower than that in taxol-treated tumors,
suggesting that EGCG could overcome taxol-induced
GRP78 expression. These data confirmed that taxol
induced GRP78 expression in vivo. Since GRP78 confers
taxol resistance, this study validated GRP78 as a target
for overcoming taxol resistance.
In addition, we investigated JNK phosphorylation in
tumors that were treated with or without EGCG and
taxol. EGCG in combination with taxol markedly
induced JNK phosphorylation in tumor tissues, whereas
phosphorylated JNK was barely detected in tumors trea-
ted with taxol or EGCG alone (Figure 6).
Discussion
Taxol has been used extensively to treat lung, ovarian
and breast cancers but drug resistance limits the clinical
usefulness of this drug. Previous studies have disclosed
some mechanisms underlying taxol resistance. Due to
its hydrophobic nature, resistance to taxol is associated
with the induction of the multidrug resistance gene
(MDR-1) encoding P-glycoprotein [28] and a decreased
cellular accumulation of taxol [29,30]. Moreover, pre-
vious studies demonstrated that several markers might
be associated with taxol sensitivity/resistance, including
p53, BRCA2, members of the epidermal growth factor
receptor (EGFR) superfamily (for example, HER2,
EGFR), estrogen receptors and progesterone receptors
[31-35]. However, retrospective clinicopathologic study
found that none of these molecular markers were pre-
dictive of response to single-agent taxane chemotherapy
in patients with metastatic breast cancer [36]. We and
others have previously found that taxol could induce the
unfolded protein response [24,25]. GRP78 is a multi-
functional protein involved in the unfolded protein
response, chemoresistance, cell proliferation and angio-
genesis. Abrogation of GRP78 induction sensitizes breast
cancer cells to taxol by potentiating the activation of
pro-apoptotic signal such as JNK phosphorylation and
caspase cleavage.
Identification of sensitizers for taxol is expected to
improve the efficacy of taxol in treating human tumors.
17-Allylamino-17-demethoxygeldanamycin (17-AAG)
inhibits Hsp90, a molecular chaperone that is important
for the posttranslational folding and stability of some
kinases, which are considered important targets for can-
cer therapy. 17-AAG, by virtue of its effects on multiple
signal transduction pathways, may therefore overcome
resistance to molecular targeted therapy. Also, previous
studies suggested that there may be additional potential
for its use in combination with conventional agents
because some of the pathways inhibited by 17-AAG are
also implicated in cytotoxic drug resistance [37]. 17-
AAG may sensitize a subset of ovarian cancer to pacli-
taxel, particularly those tumors in which resistance is
driven by Hsp90 clients such as ERBB2 and/or p-Akt
[38]. Since GRP78 is involved in taxol response, it may
be another heat shock protein that can be targeted to
improve the efficacy of taxol.
The use of a non-toxic modulator to enhance the anti-
tumor activity is invaluable in improving the outcome of
patients with cancer. Green tea has been reported to
have useful pharmacological effects such as inhibition of
carcinogenesis, chemoprevention of cancer, and antioxi-
dative effect [39-42]. EGCG and flavonoids have
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Page 6 of 10Figure 4 EGCG potentiates taxol-induced apoptosis in tumors. (a) Percent apoptosis relative to the saline-treated control tumors. Columns =
mean of apoptosis rate in tumors; bars = SE. Asterisk = P < 0.01, significantly different from control. Triangle = P < 0.001, significantly different
from taxol alone. (b) Representative TUNEL assays for tumors were shown.
Luo et al. Breast Cancer Research 2010, 12:R8
http://breast-cancer-research.com/content/12/1/R8
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ascites carcinoma cells [43]. Oral administration of
green tea can enhance the inhibitory effects of doxorubi-
cin on Ehrlich ascites carcinoma in tumor-bearing mice
[44]. The combination of EGCG and curcumin sup-
pressed tumor growth in a mouse model of human
breast carcinoma, which correlated with a significant
decrease in levels of VEGFR-1 in the tumors [45]. In
that study, tumor growth in a combination-treated
group was inhibited by 49%, while the tumor-suppres-
sing rate in an EGCG-treated group was 31% [35]. Co-
administration of EGCG and tamoxifen synergistically
suppressed tumor growth in a mouse model of human
estrogen receptor negative breast cancer (MDA-MB-
231) [26]. The tumor-suppressing rate for EGCG in
combination with tamoxifen reached 80%, while EGCG
alone inhibited tumor growth by 35% [26]. EGCG also
synergistically enhanced the inhibitory effects of sulindac
o rt a m o x i f e no nh u m a nl u n gc a n c e rc e l l s[ 4 6 ] .I no u r
study, when given at a similar dose, EGCG alone did
not inhibit 4T1 breast tumor growth. EGCG in combi-
nation with taxol resulted in a decrease in tumor weight
by 47%, whereas taxol alone inhibited tumor growth by
22.5%. In addition, the lung metastasis in mice treated
with EGCG in combination with taxol was less than
that in mice treated with vehicle or taxol alone, while
this difference was marginally significant, which might
be due to the variance in control mice. The effects of
EGCG on tumor progression may vary among different
cell types or cell lines. Also, the tumor-suppressive
effects of EGCG in combination with other agents may
depend on the nature of these compounds.
The mechanisms underlying the anticancer effects of
EGCG seem to be complex. EGCG can bind to target
molecules and trigger signaling cascades, many of which
are interconnected. It has been reported that EGCG
may bind to IGF-1R [47], GRP78 [21], Hsp90 [48], and
BCL-2 [49]. As a GRP78 inhibitor, EGCG reportedly
overcame resistance to etoposide-induced cell death in
vitro [21]. The current study demonstrates that EGCG
could sensitize breast carcinoma to taxol in a murine
model. Notably, EGCG can overcome taxol-induced
GRP78 expression, which represents another mechanism
underlying EGCG suppression of GRP78. Activation of
JNK plays critical roles in taxol-induced apoptosis.
GRP78 knockdown potentiates taxol-induced JNK
Figure 5 EGCG overcomes taxol-induced GRP78 expression in tumors. Cell lysates from dissected tumor tissues were subjected to Western
blot analysis of GRP78 expression. (a) The levels of GRP78 protein in tumors treated with vehicle, EGCG, and taxol were shown. (b) Quantitative
analysis of GRP78 expression after normalization to actin by densitometric analysis. The ratio of GRP78/actin represented by grey column was set
as 1 arbitary unit. Columns = mean of relative levels of GRP78 protein; bars = SE. Asterisk = P < 0.05 versus control. Black triangle = P < 0.05
versus taxol.
Figure 6 EGCG potentiates taxol-induced JNK phosphorylation
in tumors. Cell lysates from dissected tumors were subjected to
Western blot analysis of JNK phosphorylation. The levels of
phosphorylated JNK in tumors treated with or without EGCG and
taxol were shown.
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ates the activation of JNK in cancer cells by taxol both
in vitro and in vivo. Cell apoptosis in breast cancer
grafts is enhanced by combination of EGCG and taxol,
resulting in decreased tumor burden. Since EGCG can
target multiple molecules that are involved in cell survi-
val, one can speculate that the molecular events that are
responsible for EGCG potentiation of taxol-induced
apoptosis may involve more than one target. Non-apop-
totic cell death may also be involved in growth inhibi-
tion observed in this study. Given that taxol upregulates
GRP78 expression and that GRP78 knockdown sensi-
tizes breast cancer cells to taxol [24], it is reasonable to
suggest that inhibition of GRP78 may mediate, at least
in part, the enhancement of taxol sensitivity by EGCG.
Bioavailability is an important issue with natural che-
micals such as polyphenolic compounds. In this regard,
a prodrug of EGCG has been developed to increase the
stability, bioavailability and anticancer activities of
EGCG [50]. In addition, the bioavailability and effective-
ness of EGCG can be improved by encapsulating it in
nanoparticles [51]. The development of other bioavail-
able and stable EGCG may greatly improve its utility in
cancer prevention and therapeutics.
Conclusions
This study demonstrated that treatment with EGCG sig-
nificantly increased paclitaxel-induced JNK phosphoryla-
tion and cell death, and improved the efficacy of
paclitaxel therapy in vivo. Thus, we present an alterna-
tive approach for increasing breast cancer cell sensitivity
to paclitaxel. The efficacy of the EGCG-paclitaxel com-
bination in patients with breast cancer or other solid
tumors warrants further study.
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